Literature DB >> 6687873

Inhibition of interdigestive contractile activity in the stomach by peptide YY in Heidenhain pouch dogs.

T Suzuki, M Nakaya, Z Itoh, K Tatemoto, V Mutt.   

Abstract

The inhibitory effect of peptide YY on contractile activity in the innervated main stomach and the vagally denervated fundic pouch in conscious Heidenhain pouch dogs was investigated. Peptide YY was given in i.v. bolus injections of doses between 12.5 and 100 pmol/kg body wt. During the digestive state, 2-3 h after feeding, peptide YY was found to have no effect on contractile activity in either the innervated or the vagally denervated stomach. In the interdigestive state, it was found that peptide YY inhibited the interdigestive migrating contractions in the innervated main stomach dose-dependently for 1.2 +/- 0.1 to 5.8 +/- 0.3 min, but did not affect pouch contractions at all. This peptide, however, did not influence the cycle of the interdigestive migrating contractions. Pentagastrin, on the other hand, suppressed the interdigestive migrating contractions in the innervated main stomach when the bolus doses were greater than 300 pmol/kg body wt, but did not inhibit pouch contractions completely with this dose. Atropine (0.05 mg/kg body wt) suppressed contractions in both the main stomach and the vagally denervated pouch. Peptide YY inhibits the interdigestive migrating contractions in the stomach through the extrinsic nerves.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6687873

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  18 in total

1.  Colonic responses to enteral tube feeding.

Authors:  T E Bowling; D B Silk
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

2.  Proliferative effects of 'fibre' on the intestinal epithelium: relationship to gastrin, enteroglucagon and PYY.

Authors:  R A Goodlad; W Lenton; M A Ghatei; T E Adrian; S R Bloom; N A Wright
Journal:  Gut       Date:  1987       Impact factor: 23.059

3.  Basal and fat-stimulated plasma peptide YY levels in celiac disease.

Authors:  P J Wahab; W P Hopman; J B Jansen
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

4.  Intramural distribution of regulatory peptides in the sigmoid-recto-anal region of the human gut.

Authors:  G L Ferri; T E Adrian; J M Allen; L Soimero; A Cancellieri; J C Yeats; M Blank; J M Polak; S R Bloom
Journal:  Gut       Date:  1988-06       Impact factor: 23.059

5.  Is raised plasma peptide YY after intestinal resection in the rat responsible for the trophic response?

Authors:  A P Savage; G E Gornacz; T E Adrian; M A Ghatei; R A Goodlad; N A Wright; S R Bloom
Journal:  Gut       Date:  1985-12       Impact factor: 23.059

6.  Plasma peptide YY (PYY) in dumping syndrome.

Authors:  T E Adrian; R G Long; H S Fuessl; S R Bloom
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

7.  Enterogastrone-like effect of peptide YY is vagally mediated in the dog.

Authors:  T N Pappas; H T Debas; I L Taylor
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

8.  Dissociation of duodenogastric marker reflux and bile salt reflux.

Authors:  S A Müller-Lissner; C Fraass
Journal:  Dig Dis Sci       Date:  1985-08       Impact factor: 3.199

9.  Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon.

Authors:  T E Adrian; G H Ballantyne; W E Longo; A J Bilchik; S Graham; M D Basson; R P Tierney; I M Modlin
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

10.  Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers.

Authors:  A P Savage; T E Adrian; G Carolan; V K Chatterjee; S R Bloom
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.